Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

The advanced algorithm achieved a sensitivity of 93% and specificity of 98%. It was trained to identify up to five different valvular diseases at the same time from a single audio clip.

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR. 

The American Heart Association has developed an updated strategy for the prevention and management of cardiovascular disease. A newly defined health condition, cardiovascular-kidney-metabolic syndrome, sits at the center of that strategy. 

Preventing sudden cardiac arrest involves managing risk factors such as hypertension, hyperlipidemia and diabetes. We spoke to Christine Albert, MD, about this and much more at ESC 2023.

The announcement came just weeks after an FDA subcommittee voted in favor of approval. 

The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.

The newest additions cover conditions such as invasive breast cancer, sepsis, and abdominal aortic aneurysm, ACR announced Tuesday.